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Pharmaceutical equivalence studies, useful for checking the interchangeability of generic medicines and 
their respective innovator medicines, have been carried out in Brazil since 1999, as a consequence of 
the establishment of the generic medicine policy. For medicines containing antibiotics, microbiological 
assays are often the most appropriate method. However, the statistical methods applied in these assays 
are not widely known due to the difficult access to official codes and/or little knowledge of the statistical 
tools of analysis. Thus, the aim of this work was to compare the statistical methods for determining 
the potency of antibiotics through the cylinder-plate method using parallel lines and a three-dose level 
model, as described in the Brazilian Pharmacopeia (4th edition, 1988), British Pharmacopoeia 2011, 
European Pharmacopoeia (7th edition), The International Pharmacopoeia (4th edition), and United 
States Pharmacopeia (34th edition). The assay is illustrated with the antibiotic ofloxacin, and details 
on orthogonal coefficients, normality test, homogeneity of variance test, and detection of outliers are 
discussed. The calculations obtained by statistical analyses from different pharmacopeias lead to the 
same final interpretation. In practice, with the availability of alternative pharmacopeial methods, the 
analyst can choose the most appropriate statistical calculation to be used.
Uniterms: Antibiotics/potency. Parallel lines model. Pharmacopeial statistical methods.
Os estudos de equivalência farmacêutica, úteis na verificação da intercambialidade entre os medicamentos 
genéricos e respectivos medicamentos de referência, têm sido realizados no Brasil desde 1999, como 
consequência do estabelecimento da política de medicamentos genéricos. Para medicamentos contendo 
antibióticos, os ensaios microbiológicos são, muitas vezes, o método mais adequado. Entretanto, os 
métodos estatísticos aplicados nesses ensaios não são amplamente conhecidos devido à dificuldade 
de acesso aos compêndios oficiais e/ou pouca compreensão das ferramentas estatísticas de análises. 
Portanto, o objetivo desse trabalho foi comparar os métodos estatísticos para determinação de potência 
de antibióticos pelo delineamento por retas paralelas e três níveis de doses, descritos nas farmacopeias 
Brasileira 4. ed. (1988), Britânica 2011, Europeia 7. ed., Internacional 4. ed. e na Farmacopeia dos 
Estados Unidos 34. ed. (2011). O ensaio é exemplificado com o antibiótico ofloxacino e detalhes sobre 
coeficientes ortogonais, teste de normalidade, teste de homogeneidade de variância e detecção de 
outliers são discutidos. Os cálculos obtidos pelas análises estatísticas segundo as diferentes farmacopeias 
resultaram na mesma interpretação final. Na prática, métodos farmacopéicos alternativos permitem ao 
analista a escolha do cálculo estatístico mais apropriado a ser utilizado.
Unitermos: Antibióticos/potência. Delineamento por retas paralelas. Métodos estatísticos farmacopéicos.
M. F. V. Leonel, C. D. V. Soares, A. L. Siqueira566
INTRODUCTION
Microbiological assays on antibiotics are used in 
pharmaceutical preparations and raw materials whose 
contents are related to their biological activity and usually 
cannot be determined by chemical analyses. Typically, 
antibiotic drugs have their potency determined by com-
parison with a standard substance or a biological reference 
substance. Such potency is expressed as the ratio of the 
dose that inhibits the growth of a sensitive microorgan-
ism, relative to the standard substance dose that produces 
similar inhibition. The agar diffusion or cylinder-plate 
method used consists of a dose-response model in which 
the antibiotic concentration is proportional to the inhibi-
tion zone of microorganism growth.
The statistical analysis of such experiments re-
quires the establishment of a mathematical relationship 
of the mean responses (y) with the crescent concentra-
tions (treatments or doses) of the antibiotic. The most 
commonly used model is the parallel lines, in which 
every reference standard (S) and unknown (U) prepara-
tion should be tested with the same number of doses. 
Normally, two or three doses per preparation are used, 
and the ratio of adjacent doses should be constant for all 
treatments of the assay.
The potency calculation is based, in this case, on the 
analysis of two straight lines, one referring to the standard 
responses and the other to the unknown responses. They 
are obtained by the relationship between their responses 
and the decimal logarithm (log10) or natural logarithm (ln) 
of each of the doses (Hewitt, 2004; British Pharmacopoeia, 
2011; European Pharmacopoeia, 2011). The least squares 
method (Farias et al., 2003) is most commonly used to 
check the linearity of the curves, and, therefore, the same 
number of reference standard and unknown responses is 
used (S1, S2, S3, and U1, U2, U3). This method is still based 
on the assumption that the responses (y) follow the nor-
mal distribution (Gaddum, 1953; Farmacopeia Brasileira, 
1988; British Pharmacopoeia, 2011; European Pharmaco-
poeia, 2011) and have a constant variance (Farmacopeia 
Brasileira, 1988; British Pharmacopoeia, 2011; European 
Pharmacopoeia, 2011), and the errors are independent 
(random) (Farmacopeia Brasileira, 1988).
Evaluating these experiments involves the applica-
tion of statistical calculations currently described in phar-
macopeias. However, these calculations are not understood 
by analysts, primarily due to the unavailability of official 
codes in the pharmaceutical industries. Moreover, a lack 
of specialists in the area, together with little knowledge 
of the statistical tools of analysis, has also been observed. 
Thus, an investment in qualified personnel is extremely 
important for the pharmaceutical industry. The success of 
the experimental antibiotics assay design requires a knowl-
edge of various pharmacopeial methods, a familiarity with 
statistical hypothesis testing, and a correct interpretation 
of the validity parameters. It is worth emphasizing that 
microbiological assays of antibiotics are performed, 
among others, in studies of pharmaceutical equivalence 
for registration or renewal of generic medicines. In Brazil, 
with the advent of the generic drug policy established in 
1999, the regulatory agency admits many foreign pharma-
ceutical codes as official references for the quality control 
of raw materials and pharmaceuticals, in the absence of a 
monograph in the Brazilian Pharmacopeia. 
Normality test
A test to check the normality of the response variable 
(y) is recommended in the British Pharmacopoeia (BP) 
(British Pharmacopoeia, 2011), European Pharmacopoeia 
(EP) (European Pharmacopoeia, 2011), Brazilian Pharma-
copeia (FB) (Farmacopeia Brasileira, 1988), International 
Pharmacopoeia (IP) (The International Pharmacopoeia, 
2011), and United States Pharmacopeia (USP 34) (United 
States Pharmacopeia, 2011). In BP and EP, the work by 
Shapiro and Wilk is recommended (Shapiro, Wilk, 1965) 
for verification of the test and the calculations. Consider 
y1 < y2 < …< yn the ordered sample responses of size n 
in which i = 1, 2, ..., n and y1 is the smallest value. The 
statistic is defined as
 .  (1)
The constant b is calculated by
 , (2)
in which ai is tabulated (for n ≤ 50) in the referred cita-
tion. For normal distribution, the value of W should be 
close to 1.
Another test of normality is known as Anderson-
Darling (AD) (Minitab, 2010), which is not mentioned in 
the pharmacopeias. It is based on the cumulative distribu-
tion function (cdf) of the empirical data to be analyzed. 
In the calculation, the weighted quadratic distance is used 
between the line adjusted of the probability plot (based on 
the selected distribution) and nonparametric function. The 
statistic is defined as
, (3)
in which F is the cumulative distribution function of the 
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normal distribution of the response yi sorted in ascending 
order.
In a scale from 0 to 1, a small AD value indicates 
that normal distribution fits best the data. In cases in which 
the normality condition is not met, the transformation of 
the response (y), e.g., log10y or lny, y1/2 and y2, is suggested 
to achieve compliance with this condition (Farmacopeia 
Brasileira, 1988; British Pharmacopoeia, 2011; European 
Pharmacopoeia, 2011).
Another quantitative measure for reporting the result 
of the AD normality test is the p-value. The significance 
probability value (p) is calculated from the value obtained 
from AD’ where
 AD’ = AD (1 + 0.75/n + 2.25/ n2). (4)
The calculations are implemented in some software 
packages (Minitab, 2010) according to the following 
equations:
 13 > AD’ > 0.600,  
   p = exp [1.2937 – (5.709 x AD’) + (0.0186 x AD’2)] (5)
 0.600 > AD’ > 0.340,  
   p = exp [0.9177 – (4.279 x AD’) – (1.38 x AD’2)] (6)
 0.340 > AD’ > 0.200,  
 p = 1 – exp [– 8.318 – (42.796 x AD’) – (59.938 x AD’2)] (7)
 AD’ < 0.200,  
 p = 1 - exp [-13.436 + (101.14 x AD’) – (223.73 x AD’2)] (8)
Homogeneity of variance
The homogeneity of the variance (homocedastic-
ity) test is cited in BP and EP. Its implementation is also 
recommended by Bartlett (Bartlett, 1937) and Cochran 
(Cochran, 1951). According to Cochran, the test is based 
on the measure of the variances (si2, i = 1, …, k) between 
k treatments considered as different treatments or doses, 
of size ni, and is calculated by
 . (9)
The sizes of all ni groups are assumed to be equal 
when the calculated C is less than the critical value for a 
given significance level (Fisher, Belle, 1993).
Detecting outliers
If a response is doubtful or discrepant, it should be 
investigated. A good way to detect such observations is by 
means of graphical inspection, such as a scatter plot and/
or box plot (Ludbrook, 2008). In BP and EP the calcula-
tion of the variance of responses in each treatment group 
is suggested for the verification of outliers. FB and USP 
34 recommend the following tests.
Criterion 1 – Based on the variation of group 
with supposedly equivalent responses
For normally distributed data, different tests are 
available to identify outliers; these are sometimes called 
Q-tests (Burke, 2001). Other tests, such as the Dixon test 
(Dixon, 1950; Dixon, 1951; Bliss, 1956; Miller, 1993; 
Massart et al., 1997), are based on the calculation of the 
experimental Q (or r10 in Dixon’s notation) (Efstathiou, 
2006), defined as the ratio given by the distance of the sus-
pect value from its nearest neighbor divided by the range 
of the values. These values are compared with tabulated 
critical values. Similar to the Shapiro-Wilk test, responses 
should be sorted in ascending order. In FB and USP 34, 
the statistic is called G.
 G1 = (y2 – y1) / (yn – y1), for n = 3 to 7  (10)
 G2 = (y3 – y1) / (yn-1 – y1), for n = 8 to 13  (11)
 G3 = (y3 – y1) / (yn-2 – y1), for n = 14 to 24  (12)
If G1, G2, or G3 exceeds the critical value, for a gi-
ven significance level, such response can be eliminated. 
Otherwise, the suspect value is maintained (Farmacopeia 
Brasileira, 1988; United States Pharmacopeia, 2011).
Criterion 2 – Based on k total groups
This criterion evaluates the variation of responses in 
each treatment (Bliss et al., 1956). The biggest difference 
or range should be divided by the sum of all differences 
and must not exceed the critical value (R) (Farmacopeia 
Brasileira, 1988; United States Pharmacopeia, 2011) for k 
number of doses or treatments and n replicates.
Given the presence of outliers, the following deci-
sions can be taken: (i) to repeat the experiment, (ii) to 
reduce the number of observations by eliminating the 
entire block where the response was lost (Hewitt, 1977), 
(iii) to replace the lost response, at most one in each treat-
ment, or up to 5% (Farmacopeia Brasileira, 1988; British 
Pharmacopoeia, 2011; European Pharmacopoeia, 2011) 
or 10% (The International Pharmacopoeia, 2011; United 
States Pharmacopeia, 2011) of total responses, and re-
calculate the values. The replacement of missing values 
is also mentioned by other authors (Bliss, 1956; Finney, 
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1978; Ludbrook, 2008). Let Tr’ be the sum of all responses 
to the block (plate) in which the value is lost; Tt’ be the 
sum of all treatment responses, for which the value is lost; 
T’ be the total sum of the observations; f be the number 
of plates; and k be the number of treatments or doses. The 
value to be replaced is calculated by
y’ = (fTr’ + kTt’ – T’) / (f – 1)( k – 1). (13)
Validity test: analysis of variance
The analysis of variance (ANOVA) performed 
for calculations of antibiotic potency aims to verify the 
validity of the assay, to calculate the residual error (s2) 
(Farmacopeia Brasileira, 1988), and to distinguish the 
various sources of error (variation) affecting the responses 
that are not due to the gradual increase of doses. These 
sources can be deviations from parallelism and linearity 
(or curvature) that can occur between the reference stan-
dard and unknown responses, in addition to differences 
between preparations, blocks, and doses.
The responses are registered for each dose and for 
each preparation that comprises the total responses. The 
variation of responses due to different doses is calculated 
and subtracted from the sum of squares (SS) for each block 
to obtain the residual error. Thus, the total sum of squares 
is equal to the SS of the dose, between blocks and within 
the dose (error).
To check the significance of the sources of variation, 
SS is divided by the corresponding degree of freedom (d.f.) 
to obtain the mean square (MS), which in turn is divided by 
the residual variance (mean squared error or s2) to obtain 
the variance ratio (or F value). The F value calculated is 
compared with the critical limit obtained from Fisher’s 
statistical table (Farmacopeia Brasileira, 1988; British 
Pharmacopoeia, 2011; European Pharmacopoeia, 2011) for 
significance levels of 5% (α = 0.05) or 1% (α = 0.01) and 
depends on the source of variation. If the calculated F value 
is greater than the critical value, the source of variation is 
considered significant for the significance level adopted.
Additionally to the F statistic, the probabilities or 
p-values are recommended (Hewitt, 2004; British Phar-
macopoeia, 2011; European Pharmacopoeia, 2011). The 
procedures for the calculation of p-values are shown in 
general method of BP (A632, supplementary chapter IV 
G) and EP (general method 5.3, statistical analysis of re-
sults of biological assays and tests). The significance level 
(α) generally is 0.05 or 0.01, and for a p-value result less 
than α, the null hypothesis must be rejected. One way to 
evaluate p is first to calculate the cdf value of the data and 
then subtract it from one (1 - cdf) (Fisher; Yates, 1971).
To check the validity of the test, the regression is 
studied through the precision of the slope (C), in which 
a test with a well-defined coefficient should be close to 1 
(Farmacopeia Brasileira, 1988; British Pharmacopoeia, 
2011; European Pharmacopoeia, 2011). The use of the 
statistic g (The International Pharmacopoeia, 2011; United 
States Pharmacopeia, 2011) is also described as a positive 
number and should have a value less than 1 or less than 
0.1, indicating highly significant regression. The statistics 
C and g are related by the expression g = (C - 1)/C or C 
(1 - g) = 1. Table I shows the calculations according to 
different pharmacopeias.
To verify the linearity deviation, the parameter is ex-
pressed as two sources of variation in the pharmacopeias: 
the first, in the same direction (quadratic), and the other, 
in the opposite direction (quadratic difference). In BP and 
EP, from year 2000 on, these parameters were grouped into 
one, under the title non-linearity, requiring two degrees of 
freedom for its calculation.
The calculations according to the methods of IP and 
USP 34 are based on the use of orthogonal coefficients 
(Hewitt, 1977) to obtain the sum of squared deviations, 
which are attributed to several sources of variation. The 
coefficients are derived from the table of orthogonal poly-
nomials, e.g., as in Fisher and Yates (1971). Statistical 
analysis is exemplified in papers published by Bliss (1956) 
and Hewitt (1977). This method, easily applied, is used 
in balanced assay, and the coefficients used are applied 
when the logarithms of the doses are equally spaced. One 
of the features of such coefficients is that each line repre-
sents the contrast between individual responses, e.g., for 
the regression line, the sum of their coefficients, –1 + 0 + 
1 – 1 + 0 + 1, is zero. Each pair of contrasts is orthogonal. 
The multiplication of coefficients for the regression and 
parallelism (1, 0, –1, –1, 0, 1) is –1, 0, –1, 1, 0, 1, whose 
total is zero. The divisors (ei) are the sums of the squares 
of the coefficients of individual responses. Thus, (–1)2 + 
(0)2 + (1)2 + (–1)2 + (0)2 + (1)2 = 4.
The sums of the products of the coefficient by 
their corresponding treatment are defined as Ti. Then, its 
squared value is divided by the number of replicates, and 
its respective divisor (ei) for a, b, ab, q, and a, where a is 
the difference in the response to the reference standard and 
to the unknown; b, in this case, is the difference between 
all highest doses and all lowest doses (slope); ab is the 
difference in slope between the reference standard and the 
unknown (if the curves are parallel); q is the common cur-
vature of both preparations (if the curvatures have the same 
direction); aq is the contrast between curvatures of the two 
preparations (if the curvatures have opposite direction); 
and f is the number of replicates or block (Petri dishes).
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TABLE I - Formula for calculating the precision of the slope (C or g) used by the Brazilian Pharmacopeia (FB), The International 
Pharmacopoeia (IP), United States Pharmacopeia (USP 34), British Pharmacopoeia (BP), and European Pharmacopoeia (EP)
Parameter Pharmacopeial code Formula
C FB
 
BP and EP
  
USP 34
g IP
LS and LU, linear contrasts to the reference standard (S3 – S1) and unknown (U3 – U1) preparation; t, Student’s t for n degrees of 
freedom (d.f.) in s2; n and f, number of replicates or number of Petri dishes or blocks; d, number of doses; Tb, sums of the products 
of the coefficient eb by their corresponding treatment; eb, sums of the squares of the orthogonal coefficients of individual responses 
in Table VII; i, interval in logarithms between successive log-doses, the same for both reference standard and unknown; h, number 
of preparations including reference standard.
For the validity test, each of the rows ab, q, and aq 
values should not exceed three times the variance value 
(s2). Otherwise, if the ratio of any of the three values is 
greater than 3, then F3 should be calculated by
 , (14)
where
 s2 = [ Σy2 – (ΣTr2 / k) – (Σ Tt2/f ) + T2/N ] / n  (15)
and N is the total number of responses; n, in this case, is 
the number of degrees of freedom for residual error; k is 
the number of treatments; Tr is the sum of all responses to 
the block (plate); Tt is the sum of all treatment responses; 
and T is the total sum of the observations.
According to USP 34, F3 is applicable to a balanced 
assay with three or four dose levels. To test validity, the 
calculated F3 value must not exceed the critical value 
(United States Pharmacopeia, 2011), considering the 
number of degrees of freedom for s2. If this condition is 
satisfied, the precision of the slope C is then calculated, as 
previously reported (Farmacopeia Brasileira, 1988; British 
Pharmacopoeia, 2011; European Pharmacopoeia, 2011).
Potency
The ratio of a given reference standard dose to the 
corresponding unknown dose is designated by R. The 
logarithm of the ratio of potency of the unknown, in 
quantities assumed to be equal to those of the reference 
standard, is designated by M’ and the mathematical equa-
tions according to pharmacopeias USP 34, FB, IP, BP, and 
EP are (ci/Ta/Tb), ( –yA – 
–yP /b), (F/b), ((A – P)/3b), (ci/Ta/
Tb), respectively.
 Ideally, M’ should not significantly differ from 
zero. The logarithm of the ratio of relative potency or 
estimated potency is obtained by
 M = M’ + log R  (16)
or
 Potency (P) = antilog M = antilog M’ x R (17)
MATERIALS AND METHODS
The statistical calculations described in many 
pharmacopeias (Farmacopeia Brasileira, 1988; Brit-
ish Pharmacopoeia, 2011; European Pharmacopoeia, 
2011; The International Pharmacopoeia, 2011; United 
States Pharmacopeia, 2011) were applied to the results 
of a microbiological assay of the antibiotic ofloxacin in 
tablet preparation using the cylinder-plate method (par-
allel lines with three reference standard and unknown 
doses). The dilutions of the unknown (U), tablets labeled 
potency claimed 400 mg (R), and reference standard 
(S) were prepared at concentrations of (1) 20 µg mL-1, 
(2) 30 µg mL-1, and (3) 45 µg mL-1. Each of the six doses 
was placed once in each block (Petri dish), up to a total 
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of seven Petri dishes. Table II describes the diameters of 
inhibition zones (y), in millimeter (mm), in addition to 
the total treatment values (columns), means, and range 
(difference between maximum and minimum) for each 
treatment.
To evaluate the results, preliminary calculations are 
presented for the purpose of preparing the tables required 
to complete the results. Calculations and graphs were per-
formed using Excel and Minitab (Minitab, 2010).
CALCULATION AND RESULTS
Normality test
First, for the Shapiro-Wilk method, the treatment 
columns (doses) were sorted in ascending order (Table 
III). For the low-reference standard dose (S1), the sorted 
responses were 14.80, 15.13, 15.14, 15.18, 15.24, 15.57, 
and 15.61, and the sum of the squared deviations of the 
responses was 0.4651. In the third column, the responses 
were sorted in descending order, n-i+1, until the fourth 
observation, and, in the fourth column data, are shown in 
ascending order until the fourth observation. The sum of 
the last column represents the constant B, i.e., the sum of 
the values obtained by multiplying the coefficients ai by 
the difference between yn-i+1 and yi. (0.6523). The coef-
ficient b2 is 0.4255 and the statistic W, applying equation 
(1), is
 W = 0.4255/0.4651 = 0.915.
The graph of normal probability for the S1 dose was 
obtained and is shown in Figure 1.
TABLE II – Diameters of inhibition zone (mm) of the ofloxacin microbiological assay using three-dose level (3x3)
Plate
Doses (µg mL-1)
S1 (20) S2 (30) S3 (45) U1 (20) U2 (30) U3 (45)
1 14.80 17.93 19.76 15.39 17.35 20.72
2 15.13 18.33 20.57 14.98 17.72 21.39
3 15.57 18.22 21.55 15.02 18.52 20.67
4 15.61 18.51 20.73 15.12 18.14 20.59
5 15.24 18.47 20.72 15.26 18.23 20.87
6 15.18 18.19 20.63 14.64 18.12 21.23
7 15.14 17.69 20.38 14.80 17.78 20.74
Total 106.67 127.34 144.34 105.21 125.86 146.21
Mean 15.24 18.19 20.62 15.03 17.98 20.89
Range 0.81 0.82 1.79 0.75 1.17 0.80
S, reference standard; U, unknown.
TABLE III - Sorted results for calculation of coefficient b of 
the reference standard dose responses, S1, for the ofloxacin 
microbiological assay
i n – i + 1 yn – i + 1 yi ai ai(yn – i + 1 – yi) 
1 7 15.61 14.80 0.6233 0.5049
2 6 15.57 15.13 0.3031 0.1334
3 5 15.24 15.14 0.1401 0.0140
4 4 15.18 15.18 0.0000 0.0000
i, ordered ith response; n, number of observations; y, responses; 
ai, coefficient used in the W statistic.
FIGURE 1 - Chart of normal probability of the S1 dose (diameter 
of inhibition zone, mm) at 20 µg mL-1, for the ofloxacin 
microbiological assay
After the statistical value AD was calculated, the 
p-value was calculated for the other treatment groups. 
Initially, cdf values were calculated, then, the p-value was 
obtained by subtracting (1 - cdf).
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TABLE IV - Statistics obtained for each dose for the ofloxacin microbiological assay, using three-dose level (3x3)
Parameter
Doses (µg mL-1)
S1 (20) S2 (30) S3 (45) U1 (20) U2 (30) U3 (45)
0.4651 0.5189 1.6868 0.3982 0.9038 0.5558
b2 0.4254 0.4818 1.5827 0.3723 0.8721 0.4750
W 0.915 0.928 0.938 0.935 0.965 0.854
AD 0.380 0.271 0.439 0.132 0.225 0.523
p 0.295 0.548 0.201 0.960 0.712 0.117
s2 0.0775 0.0865 0.2811 0.0664 0.1506 0.0926
G1a 0.407 0.293 0.346 0.213 0.316 0.100
G1b 0.049 0.049 0.458 0.173 0.248 0.200
S, reference standard; U, unknown; b2, square of the constant used in the Shapiro-Wilk test (W); AD, Anderson-Darling test statistic; 
p, Anderson-Darling test p-value; s2, variance; G1a, Dixon’s statistic for the first observation; G1b, Dixon’s statistic for the second 
observation.
AD’ was estimated according to equations (4) and 
(6), taking the value of statistic AD (0.439), for the S3 dose.
AD’ = 0.439 (1 + 0.75/7 + 2.25/49) = 0.5062 
p = exp [0.9177- (4.279 x 0.5062) – (1.38 x 0.50622)] = 0.201
Homogeneity of the variance test
Since each treatment in the assay is a sampling val-
ue, the variances for each treatment group were calculated. 
According to equation (9), the following was obtained:
CCochran = 0.0775/0.7547 = 0.103
Table IV summarizes the results of ; 
constant B2; statistics W, AD, G; probability p; and vari-
ance (s2) for all treatment groups in the assay.
Detecting outliers
To detect outliers by criterion 1, the responses 
were sorted in ascending order. The maximum difference 
(range) was then calculated for each treatment. It was 
observed that for the high reference standard dose (S3) 
there were responses that could be considered possible 
outliers, e.g., values 19.76 mm and 21.55 mm. In the box 
plot of Figure 2, one can notice the presence of such two 
points for the S3 dose.
Hence, the ordering of data for verification, in mm, 
is 19.76, 20.38, 20.57, 20.63, 20.72, 20.73, 21.55. Con-
sidering the first observation as a suspect value (lower 
value), 19.76 mm, G1 (n = 7) was estimated, according to 
equation (10):
G1 = (20.38 – 19.76) / (21.55 – 19.76) = 0.346. 
For the second suspect value (higher value), 21.55, 
G1 is
G1 = (21.55 – 20.73) / (21.55 – 19.76) = 0.458.
Table IV shows the calculated values of G1 for high 
S3 dose and for the other treatment groups.
For verification by criterion 2, considering that the 
S3 dose showed the largest variation, the R-value was cal-
culated by the ratio of the maximum range and the sum 
of all ranges.
R = 1.79/6.14 = 0.292
FIGURE 2 - Box plot of the S3 (reference standard) and U3 
(unknown) doses at 45 µg mL-1, for the ofloxacin microbiological 
assay.
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Replacing outliers
The calculation for the replacement of the responses 
y = 19.76 to 21.55 of dose S3 values, identified as outliers 
in the box plot (Figure 2), was carried out. The responses 
resulted in the order (---; 20.57; ---; 20.73; 20.72; 20.63; 
20.38), excluding the outliers.
The average of the remaining five responses was 
20.61, and this value was inserted into the first gap to 
calculate the third gap. The new order is now (20.61; 
20.57; ---; 20.73; 20.72; 20.63; 20.38), and the sum of 
total responses is 123.64.
Applying equation (13), the value of the third gap 
was recalculated:
y’ = [(7 x 88) + (6 x 123.64) – 734.93] /  
[(7 – 1)(6 – 1)] = 20.76,
for which Tr’ = 88 (109.55 – 21.55); Tt’ = 123.64 (145.19 
– 21.55); and T’ = 734.93; f = 7; k = 6.
Eliminating the value added in the first column 
(average 20.61) in place of the response y = 19.76, the fol-
lowing sequence (---; 20.57; 20.76; 20.73; 20.72; 20.63; 
20.38) was obtained. To calculate the new value of the first 
gap, and again applying the pharmacopeial calculations, 
this value became
y’ = [ (7 x 86.19) + (6 x 123.79) – 735.08] /  
[(7 – 1)(6 – 1)] = 20.37.
The S3 treatment values, after replacement of dis-
crepant responses, became (20.37; 20.57; 20.76; 20.73; 
20.72; 20.63; 20.38).
However, for calculations of ANOVA and potency 
of the unknown, the responses 19.76 and 21.55 were not 
replaced. The two observations have not been pointed out 
as outliers in the Dixon test (criterion 1). Additionally, the 
responses were found to be homoscedastic in the test of 
variance homogeneity.
Analysis of variance 
Tables V and VI show the results of the ANOVA 
performed according to FB, BP and EP respectively, con-
sidering all possible sources of variation.
Table VII shows the results of the sum of squares 
allocated to sources of variation due to preparation, re-
gression, parallelism, and curvature in the same direction 
and opposite direction, following calculations using the 
orthogonal coefficients recommended by IP and USP 34.
The total values (Ti2/ei f) for ab, q, and aq were 
0.396, 0.188 and 0.135, respectively. The ratios of each 
total to the variance (0.096), as in equation (15), were 
4.125 (0.396/0.096), 1.958 (0.188/0.096), and 1.406 
(0.135/0.096). Considering that the ratio of total value 
of ab to the variance (4.125) was greater than 3, F3 was 
calculated according to equation (14):
F3 = (0.396 + 0.188 = 0.135) / (3 x 0.096) = 2.50.
DISCUSSION
Normality test
The values of W statistics, according to the Shap-
iro-Wilk test, were greater (values near 1) than the critical 
TABLE V - Analysis of variance (ANOVA) for the ofloxacin microbiological assay according to the Brazilian Pharmacopeia (FB)
Source of variation d.f.a MSb Fc Limiting valued
Limiting 
valuee p-value
f
Preparation 1 0.027 0.28 <4.17 - 0.598
Regression 1 221.035 2.300 - >7.56 0.000
Non-parallelism 1 0.396 4.12 <4.17 - 0.051
Quadratic curvature 1 0.188 1.95 <4.17 - 0.173
Difference of quadratic 1 0.135 1.41 <4.17 - 0.244
Treatments (between doses) 5 44.356 457.70 >2.53 - 0.000
Blocks 6 0.274 2.85 - <3.47 0.026
Error (within doses) 30 0.096 - - - -
Total 41
a: d.f., degrees of freedom; b: MS, mean square; c: F, variance ratio; d: critical F-value at significance level 0.05; e: critical F-value 
at significance level 0.01; f: p, calculated probability.
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TABLE VII - Coefficients and orthogonal contrasts for the ofloxacin microbiological assay, according to the International 
Pharmacopoeia (IP) and the United States Pharmacopeia (USP 34)
Source of 
variation Orthogonal coefficients ei Ti Ti
2/ei f 
a -1 -1 -1 1 1 1 6 -1.07 0.027
b -1 0 1 -1 0 1 4 78.67 221.035
ab 1 0 -1 -1 0 1 4 3.33 0.396
q 1 -2 1 1 -2 1 12 -3.97 0.188
aq -1 2 -1 1 -2 1 12 3.37 0.135
a, difference between reference standard and unknown; b, difference between all highest and lowest doses (slope); ab, difference 
between slopes; q, common curvature of both preparations; aq, contrast between curvature of the two preparations; ei, sum of 
squares of coefficients in each row; Ti, sum of the products of individual coefficients in each row with their corresponding total 
treatment; f, number of replicates or block (Petri dishes).
TABLE VI - Analysis of variance (ANOVA) for the ofloxacin microbiological assay according to the British Pharmacopoeia (BP) 
and the European Pharmacopoeia (EP)
Source of variation d.f.a MSb Fc Limiting valued
Limiting 
valuee p-value
f
Preparation 1 0.027 0.28 <4.17 - 0.601
Regression 1 221.032 2300.91 - >7.56 0.000
Non-parallelism 1 0.396 4.12 <4.17 - 0.051
Non-linearityg 2 0.161 1.68 <3.32 - 0.203
Treatments (between doses) 5 44.356 457.70 >2.53 - 0.000
Blocks 6 0.275 2.86 - <3.47 0.025
Error (within doses) 30 0.096 - - - -
Total 41
a: d.f., degrees of freedom; b: MS, mean square; c: F, variance ratio; d: critical F-value at significance level 0.05; e: critical F-value 
at significance level 0.01; f: p, calculated probability; g: same direction and opposite direction.
value (W is 0.803 for α = 0.05) (Shapiro & Wilk, 1965). 
The chart of normal probability (Figure 1) represents the 
responses for dose S1 (x-axis) versus percentages (y-axis) 
of the values that are less than or equal to them, along 
the reference line (central line). The plotted points form a 
reasonably straight line and the p-value for statistics AD 
was 0.380. A normal distribution with a mean of 15.24 
and a standard deviation of 0.2784 appeared to fit the data 
well. The probability p calculated for all treatment groups 
was greater than the significance level α = 0.05, as shown 
in Table IV. Thus, the responses were not transformed. 
One can state that the unknown preparation comes from 
a normal population (p > 0.100), at a significance level 
of 5%.
Homogeneity of variance test
The statistic value according to Cochran (C = 0.372) 
was lower than the critical value (C is 0.418 for d.f. = 6 
and α = 0.05) (Fisher, Belle, 1993). Although there was a 
discrepant difference for dose S3, the null hypothesis of 
equality of variances was not rejected, i.e., the data did 
not provide enough evidence that the treatments presented 
different variances.
Detection and replacement of outliers
In the test for the detection of outliers, the results 
led to conflicting interpretations. Calculations made by 
criterion 1 suggested that the responses listed as discrep-
ant (19.76 and 21.55) were consistent with the rest of the 
data and should not be eliminated, because the calculated 
values of G1, i.e., G1a = 0.346 and G1b = 0.458 (Table IV), 
were smaller than the critical value (G1 is 0.586 for n = 7) 
(Farmacopeia Brasileira, 1988; United States Pharmaco-
peia, 2011).
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By criterion 2, however, the R-value (0.292) was 
greater than the critical value (R was 0.288 for n = 7 and 
k = 6) (Farmacopeia Brasileira, 1988; United States 
Pharmacopeia, 2011), suggesting that the responses are 
not consistent with other data and should be treated as 
outliers. The option to null and to replace these values is 
not recommended, since the data were not fully recog-
nized as outliers (Ludbrook, 2008), i.e., both criteria were 
contradictory. In the case of loss of some responses, the 
replacement of missing values is justified to avoid break-
ing the orthogonality (Finney, 1978). Otherwise, this may 
hamper the use of orthogonal coefficients in the ANOVA. 
In an evaluation of the data obtained, it was found that (i) 
the tests of normality and homogeneity of variance were 
satisfactory, and (ii) the replacement of two dose responses 
in the S3 column contradicted the recommendation of the 
pharmacopeia that advocates “to replace the lost response, 
at most one in each treatment or, up to 5% or 10% of total 
responses”. Thus, an option was made to keep the data 
originally obtained in the assay by accepting them as a 
genuine and predictable part of the experimental data.
To check the impact on the replacement of these 
responses, values were replaced from 19.76 and 21.55 to 
20.37 and 20.76, respectively. The replacement of such 
responses did not significantly alter the potency, but the 
ANOVA showed a relevant deviation from parallelism (F 
calculated was 6.54, greater than the critical value F criti-
cal = 4.17) between the reference standard and unknown 
regression lines.
Analysis of variance 
Considering ANOVA in all pharmacopeial methods, 
observations were made for each source of variation, as 
follows:
Preparation: The calculated F-value (F = 0.28) was 
lower than the critical value (F1,30;0.05 = 4.17) (Farmacopeia 
Brasileira, 1988; British Pharmacopoeia, 2011; European 
Pharmacopoeia, 2011). This indicates that the preparations 
are similar or that the unknown has a potency close to that 
of the reference standard.
Regression: The calculated F-value (F = 2300) was 
higher than the critical value at 1% significance level 
(F1,30;0.01 = 7.56) (Farmacopeia Brasileira, 1988; British 
Pharmacopoeia, 2011; European Pharmacopoeia, 2011), 
indicating that the dose-response curve was highly signifi-
cant. Table VIII shows the values of common slope b. The 
calculation was not performed according to USP 34, since 
this parameter is not a requirement for testing the validity 
of the model by parallel lines–balanced assay, according to 
general methods of the pharmacopeia. The significance of 
the regression was confirmed by statistic C or g, i.e., C is 
very close to 1 and g is less than 1. Considering the aver-
age of C (1.002) and g (0.002) in Table VIII, the value for 
expression C (1 - g) is 0.999996 or [1.002 (1 - 0.002)] ≈ 1.
Deviation from parallelism: Ideally, lines should be 
completely parallel, and there should be no deviation from 
parallelism. Therefore, a difference of at least one unit 
in the F-value calculated for the critical value should be 
established. The calculated F-value (F = 4.12) was lower, 
but very close to the critical value (F1,30;0.05 = 4.17) (Farma-
copeia Brasileira, 1988; British Pharmacopoeia, 2011; 
European Pharmacopoeia, 2011). In the graph response 
versus concentration it was observed that lines cross 
each other, suggesting a possible deviation of parallelism 
(Figure 3). The calculated F-value (4.12) was very close 
TABLE VIII - Comparative results of common slope and precision of the slope (g or C) according to several pharmacopeial codes, 
applied for the ofloxacin microbiological assay
Parameter
Pharmacopeial code
IP USP 34 BP and EP FB
Common slope 15.958 NR 15.956 15.956
Precision of the slope g = 0.002 C = 1.001 C = 1.002 C = 1.002
NR, not required.
FIGURE 3 - Regression curves fitted to the ofloxacin 
microbiological assay, using three-dose level (3x3) for the 
reference standard (S) and unknown (U) preparations.
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to the critical value, indicating a deviation of parallelism, 
i.e., it exists, but is not significant. The p-value was greater 
than 0.05, confirming that the deviation from parallelism 
is not significant.
Deviation from linearity: No deviation in the same 
direction and opposite direction was observed because the 
calculated F-values (F = 1.95 and 1.41) were smaller than 
the critical value (F1,30;0.05 = 4.17) (Farmacopeia, 1988). 
According to BP and EP, the calculated F-value (1.68) was 
also smaller than the critical value (F2,30;0.05 = 3.32) (British 
Pharmacopoeia, 2011; European Pharmacopoeia, 2011).
Treatments: The calculated F-value (F = 457) was 
greater than the critical value (F5,30;0.05 = 2.53) (Farmaco-
peia, 1988; British Pharmacopoeia, 2011; European Phar-
macopoeia, 2011), indicating that it is a major influence 
on the regression curve, as expected.
Blocks (plates): According to FB, BP, and EP, 
the calculated F-values (F = 2.84 and 2.85) were lower 
than the critical value (F6,30;0.01 = 3.47) (Farmacopeia 
Brasileira, 1988; British Pharmacopoeia, 2011; European 
Pharmacopoeia, 2011). Hence, there is no difference in 
the experimental model due to the source of variation, 
blocks. Even if it existed, the assay would not be consid-
ered invalid, since each block is an experimental unit that 
includes all doses, one for each treatment. Therefore, this 
is an independent assay, the differences of which affect 
the treatments equally. Considering that every source of 
variation that affects the response can influence the slope, 
the differences between blocks are adjusted when using 
the balanced model.
For the interpretation of the validity of the assay, ac-
cording to IP and USP 34, only the analysis of sources of 
variation parallelism, and linearity deviation in the same 
direction and opposite direction are taken into consideration. 
The sum of squared deviations, obtained by using orthogo-
nal coefficients (USP 34), is equivalent to all other sources 
of variation based on the least squares method, denoted by 
the pharmacopeias BP, EP, and FB. The found F3-value 
(2.50) is smaller than the critical value (F3 is 2.92 for d.f. = 
30) (United States Pharmacopeia, 2011), which determines 
that there are no parameters that invalidate the assay.
Evaluation of potency and confidence limits
As expected, the results from the application of 
pharmacopeial statistical methods are quite similar. The 
expressions for the potency calculations adopted by the 
pharmacopeias are apparently different, but the variables 
have the same meaning and are therefore related. Equal-
ity demonstrations of these expressions have not been 
presented in this work.
The ANOVA indicated no difference between the 
potency of the reference standard and sample prepara-
tion of ofloxacin tablets. The results of relative potency 
(antilog M’ x R; R = 400 mg) and their confidence limits 
(in percentage), according to each pharmaceutical code, 
are as follows: FB, 99.27 (96.50 to 102.11); BP and EP, 
99.27 (96.50 to 102.11); IP, 99.28 (97.22 to 102.86); and 
USP 34, 99.27 (96.50 to 102.11).
CONCLUSION
The reliability of the results of antibiotic potency 
assays depends on the control of the variables that can 
affect such results. The replacement of outliers should 
not be a rule, especially when the results of ANOVA are 
satisfactory and do not invalidate the assay performed. It 
is important to note that the outliers are random and that 
replacement does not result in biased results. Therefore, 
the decision to accept or reject the data, presumably 
atypical, should be based on statistical analysis, as well 
as reasonable and appropriate interpretation of results by 
an experienced analyst.
For the parallel lines and three-dose level model, 
according to the pharmacopeias cited, one must observe 
that (i) the statistical calculations for determination of 
antibiotic potency are based on the regression analysis us-
ing the least squares method and on the use of orthogonal 
coefficients suitable for the balanced model; and (ii) the 
different statistical methods used are similar regarding 
the results obtained for potency and confidence interval.
It is important to mention that alternative statisti-
cal methods, as long as they are valid, are recognized by 
pharmacopeias. Finally, this work is a contribution to the 
choice of the most appropriate statistical calculation to 
be used.
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